Lenoxin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lenoxin

Quick Facts

Property Description
Active ingredient Digoxin
Form Tablet, Solution for injection
Pharmacological class Cardiac Glycoside, Cardiotonic Agent
General purpose Improving the heart's pumping efficiency and rhythm
Origin Derived from Digitalis lanata

What Type of Medicine is Lenoxin (Digoxin)?

Lenoxin is a well-established, prescription-only cardiovascular medication whose single active ingredient is Digoxin, a potent compound with the chemical structure C41H64O14. This medication belongs to the specific pharmacological class of Cardiac Glycosides, sometimes referred to as Digitalis glycosides, and is further classified as a Cardiotonic Agent. The substance is derived from the Digitalis lanata plant, indicating its origin as a semi-synthetic compound. Digoxin remains a critical therapy for individuals requiring specialized cardiac support.


What is Lenoxin’s General Therapeutic Purpose?

The primary therapeutic purpose of Lenoxin is to enhance the functional capacity of the heart by directly influencing its strength and rhythm. This action is rooted in the drug’s ability to induce a vital dual effect on the cardiovascular system. Lenoxin achieves a positive inotropic effect, meaning it strengthens the force of myocardial contraction to facilitate more efficient blood circulation throughout the body. Concurrently, it exerts a negative chronotropic effect by slowing the heart rate. This core mechanism involves the specific inhibition of the Na^+K^+-ATPase pump in cardiac cells. This combined action ensures the heart operates more powerfully, regularly, and sustainably.


Available Forms: Tablet and Injectable Solution

Lenoxin is manufactured and supplied in pharmaceutical preparations suitable for systemic delivery, serving both maintenance and acute clinical needs. The drug is most commonly provided as an oral tablet for long-term daily management and as a sterile solution for injection for intravenous administration when rapid onset of action is required. The existence of these two distinct preparations—oral versus intravenous—is a differentiating factor, allowing medical professionals to manage patient care across different clinical settings. These forms ensure that the single-ingredient product can be precisely delivered for maximum therapeutic impact.

What side effects are possible with Lenoxin?

Official Documentation of Safety and Adverse Effects

The safety profile of Lenoxin (Digoxin), as documented in official government regulatory texts, centers on its narrow therapeutic index, with cardiac events representing the most serious safety concern. Overall, the incidence of adverse reactions in clinical use is officially reported within the range of 5% to 20%, with serious events accounting for a segment of this range.


Adverse Reactions by System and Frequency

Side effects are classified by the physiological system affected, according to official regulatory categorization:

  • Cardiac Disorders: The most serious reactions include cardiac arrhythmias such as ventricular fibrillation, advanced heart block, and severe sinus bradycardia. These reactions define the drug's critical toxicity syndrome.
  • Common Effects (1% to 10%): Effects frequently documented in regulatory sources include gastrointestinal disturbances (nausea, vomiting, anorexia, diarrhea), CNS effects (dizziness, headache), and visual disturbances (blurred vision, altered color perception, specifically yellow-green predominance).
  • Rare Effects: Less common reactions noted in official documentation include thrombocytopenia and, rarely, intestinal hemorrhagic necrosis or psychotic disorders.

Safety Considerations for Specific Populations

Official prescribing information highlights specific contexts that increase the risk of toxicity:

  • Renal Impairment: Patients with decreased kidney function are noted to be at increased risk because the drug is primarily eliminated by the kidneys.
  • Electrolyte Status: Toxicity is officially exacerbated by coexisting conditions such as low potassium (hypokalemia), low magnesium (hypomagnesemia), and high calcium (hypercalcemia).
  • Geriatric and Pediatric Patients: Older adults are often more susceptible to side effects. In children, cardiac arrhythmias are officially the earliest and most frequent manifestation of excessive dosing.

These official regulatory domains structure the understanding of Lenoxin's risk, emphasizing the importance of managing patient-specific factors documented in the product labeling.

Overdose and Emergency Response

Overdose with Lenoxin (Digoxin) is officially documented to involve distinct clinical and physiological manifestations. Cardiac toxicity is a severe outcome, encompassing various arrhythmias and conduction disturbances, ranging from sinus bradycardia and atrioventricular (AV) block to potentially fatal ventricular fibrillation. Non-cardiac presentations commonly include gastrointestinal effects such as nausea, vomiting, anorexia, and diarrhea. Neurological and visual disturbances are also recognized, including dizziness, confusion, and color vision aberrations like xanthopsia. Laboratory findings frequently include significant hyperkalemia.

Immediate medical attention is mandated upon the observation of any symptomatic bradyarrhythmia or heart block. For severe or life-threatening toxicity, hospital admission is required. Management involves symptomatic and supportive treatment and the immediate correction of contributing factors, notably electrolyte imbalances such as hypokalemia and hypomagnesemia. Digoxin Immune Fab (Ovine) is officially indicated as the antidote for life-threatening overdose.

Regulatory documents specify that patients with advanced age or impaired renal function are at increased risk for toxicity. Furthermore, continuous cardiac monitoring, serial electrocardiograms (ECGs), and assessment of serum electrolytes and renal function are required during management.

Therapeutic Uses of Lenoxin

Main Uses of Lenoxin

Lenoxin is a medication containing the active ingredient digoxin, which belongs to a class of drugs known as cardiac glycosides. It is primarily used to manage specific conditions affecting the heart's rhythm and its ability to pump blood effectively.

Heart Failure

One of the primary applications of Lenoxin is in the management of chronic heart failure. In this condition, the heart muscle is unable to pump enough blood to meet the body's needs. Lenoxin works by increasing the force of the heart muscle's contractions, which helps the heart circulate blood more efficiently throughout the body.

Atrial Fibrillation and Flutter

Lenoxin is also used to treat certain types of irregular heartbeats (arrhythmias), specifically atrial fibrillation and atrial flutter. These conditions involve rapid and irregular electrical activity in the upper chambers of the heart (the atria). The medication helps to slow down the heart rate and stabilize the rhythm by affecting the electrical signals that coordinate the heartbeat.

Benefits of Treatment

When used as part of a comprehensive management plan, Lenoxin offers several clinical benefits aimed at improving cardiac function and patient stability.

  • Improved Pumping Efficiency: By strengthening the heartbeat, the medication helps alleviate symptoms associated with poor circulation, such as shortness of breath and fluid retention.
  • Heart Rate Regulation: In cases of rapid arrhythmias, Lenoxin helps maintain a more stable and controlled heart rate, which can reduce the sensation of heart palpitations.
  • Enhanced Exercise Tolerance: By improving the overall efficiency of the cardiovascular system, patients may find they are better able to engage in daily physical activities with less fatigue.
  • Reduced Hospitalizations: For individuals with chronic heart failure, consistent management with medications like Lenoxin can help stabilize the condition and reduce the frequency of acute episodes that require hospital care.

Regulatory References

  1. Label: DIGOXIN tablet via DailyMed

Eligibility and Restrictions for Use

This medication's eligibility is strictly defined by regulatory contraindications and restrictions related to a patient’s existing health status, regardless of the condition being treated.

Populations Who Must Not Use Lenoxin

Use of Lenoxin is contraindicated (prohibited) for individuals with:

  • Ventricular Fibrillation (a type of dangerous, rapid heart rhythm).
  • A Known Hypersensitivity or severe allergic reaction to digoxin or any other medicine from the digitalis class.
  • Specific cardiac conduction abnormalities, such as an accessory atrioventricular (AV) pathway (like Wolff-Parkinson-White syndrome), which increases the risk of ventricular fibrillation.

Eligibility Restrictions and Special Considerations

  • Condition-Specific Restrictions: The medicine is not recommended in patients with acute myocardial infarction or myocarditis. It is also restricted in patients with Hypertrophic Obstructive Cardiomyopathy (HOCM) unless concomitant atrial fibrillation and heart failure are present.
  • Renal Impairment: Since Lenoxin is primarily excreted by the kidneys, patients with impaired renal function require special caution and a lower dose, as they are at a higher risk for toxicity.
  • Age-Related Rules: Dosing for geriatric patients and pediatric patients must be selected cautiously, taking into account factors like lean body weight and renal function. Newborn infants are noted to display variability in tolerance. Geriatric patients may require careful monitoring for side effects and consideration of reduced renal function.

What should I know about interactions with other medicines?

Lenoxin (Digoxin) interactions are officially documented based on pharmacokinetic changes that alter systemic exposure and pharmacodynamic effects that modify the heart's rhythm. The most significant interactions alter systemic exposure through interference with the P-glycoprotein (P-gp) efflux transporter, as Lenoxin is a P-gp substrate. Substances that inhibit P-gp, such as Amiodarone, Quinidine, and Verapamil, reduce the clearance of Lenoxin, leading to a substantial increase in its plasma concentrations. Conversely, P-gp inducers, including Rifampin and the herbal product St John's wort, may reduce Lenoxin exposure. Certain food products, such as meals high in insoluble fiber, are documented to reduce the drug's oral absorption.

A distinct set of interactions involve pharmacodynamic effects, where co-administration with other medications that affect the atrioventricular (AV) node may result in additive effects, increasing the risk of bradyarrhythmias. Additionally, the rapid intravenous administration of Calcium is noted to induce severe arrhythmias. Due to its primary renal excretion, the risk of altered exposure is heightened in patients with impaired renal function. For procedural consistency, monitoring of serum concentration requires blood sampling at least six hours or later after the last dose. Formal restrictions include not administering the drug in the presence of Ventricular fibrillation.

Mechanism of Action

️ Modulating the Heart Muscle's Energy Pump

Lenoxin's primary action involves the direct inhibition of the Sodium-Potassium ( Na^+/ K^+) ATPase enzyme found in cardiac cell membranes. This enzyme blockade initiates a mechanistic cascade by increasing the amount of sodium ( Na^+) inside the cell. This increase in intracellular Na^+ then indirectly reduces the efficiency of the Sodium-Calcium Exchanger ( NCX), leading to a higher concentration of intracellular calcium ( Ca^2+). This sequence of events leads directly to the physiological effect of increased force of myocardial contraction (positive inotropy).


Influencing Electrical Conduction via Nerve Signals

In addition to its effect on the cardiac muscle pump, Lenoxin also engages the Autonomic Nervous System by enhancing the activity of the vagus nerve (cholinergic pathway). This neural modulation primarily affects the atrioventricular ( AV) node, which is the electrical gateway between the heart's upper and lower chambers. The resulting physiological consequence is a slowing of electrical signal conduction through the AV node, which results in a reduction in the rate of electrical signal transmission across the AV node.

Dosage and Administration Information

How Lenoxin (Digoxin) is Officially Used

The administration of Lenoxin is defined by established protocols to ensure effective therapeutic concentration and proper delivery. The medicine is available for oral use, primarily as a tablet for long-term maintenance, and as an Intravenous (IV) solution for rapid treatment initiation, known as digitalization.


Dosing and Scheduling Principles

Therapy generally involves distinct phases. A loading dose of up to 1500 mcg (1.5 mg) is given in divided fractions over 24 hours for quick effect, followed by a long-term maintenance dose. The standard adult maintenance dose ranges from 125 mcg to 250 mcg (0.125 mg to 0.25 mg) and is typically administered once daily.


Administration Requirements and Adjustments

Route Specifics: The IV solution must be administered slowly over a period of five minutes or longer. For long-term oral therapy, consistency is key, and the tablet should be taken at the same time each day. While it can be taken with or without food, clinical labeling advises against concurrent use with high-fiber bran meals, which can interfere with absorption.

Dose Adjustment: Official instructions mandate that the dose must be reduced for patients with impaired kidney function, with the precise maintenance dose determined by the patient's estimated creatinine clearance. Lower starting doses are often used in older adults due to anticipated reduced renal function.

Proper Use: If a patient misses a scheduled dose, they should take it within 12 hours. If more than 12 hours have passed, the missed dose should be skipped to prevent excessive accumulation, and the patient should resume the next day’s scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lenoxin (Digoxin)


Evidence for Use in Chronic Heart Failure

This section describes the types of research for Lenoxin in chronic heart failure, focusing on what key randomized trials and analyses examined, including outcomes related to hospitalizations and changes in functional status.

Lenoxin was evaluated through large-scale Randomized Controlled Trials (RCTs) compared to placebo in adults with chronic heart failure and a reduced pumping ability. Researchers monitored the frequency of hospitalizations for worsening heart failure and all-cause mortality over several years. The key RCTs reported measurements that aligned with a lower rate of hospital admissions due to heart failure. However, the largest trials described a neutral finding when tracking survival between the groups receiving the drug and those receiving the placebo.


Evidence for Controlling Rapid Heart Rhythms

This part will outline the types of studies that exist for using Lenoxin to manage the speed of the lower heart chambers (the ventricular rate), detailing the primary measures examined, such as heart rate changes and how symptoms evolved in studies.

Research exploring Lenoxin’s use to manage the ventricular rate in conditions like Atrial Fibrillation and Atrial Flutter includes smaller Randomized Clinical Trials (RCTs) and a large amount of observational studies. The research primarily examined the acute and sustained management of the heart rate and reported on how symptoms, such as the perceived discomfort of palpitations, evolved. Trials reported measurements that reflected changes in the ventricular heart rate when studied. However, observational studies reported varying patterns of association with long-term clinical events, including all-cause mortality and hospitalizations, contributing to uncertainty in this area.


Gaps in Research and Areas of Uncertainty

A key gap is the lack of recent, definitive RCTs integrating Lenoxin into contemporary treatment protocols for heart failure, as foundational medications have changed since the original trials. The long-term outcomes in the context of Atrial Fibrillation remain uncertain due to the conflicting nature of findings derived from large observational studies versus limited randomized data. Furthermore, data for certain groups remain insufficient, particularly specific information from randomized trials for patients with certain severe kidney conditions or other complex comorbidities. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Lenoxin (FAQ)

Q: What happens if I stop taking Lenoxin suddenly?

Regulatory information advises that stopping Lenoxin therapy suddenly may lead to a worsening of the underlying condition. Therefore, any change to your regimen must only be done under the direction of a healthcare professional.

Q: Can I take Lenoxin with my daily vitamins and supplements?

Official labeling cautions about potential interactions with various substances, including certain herbal products like St. John’s Wort and supplements containing calcium. It is important to inform a healthcare provider about all vitamins, minerals, and supplements you are taking, as many of these can potentially alter how Lenoxin is absorbed or cleared by the body.

Q: Is there a generic version of Lenoxin available?

Yes. The active ingredient in Lenoxin is Digoxin, and the U.S. Food and Drug Administration (FDA) has approved generic versions of the tablet and injectable formulations. Generic products are certified to meet the same strict standards for quality, strength, and performance as the brand-name product.

Q: Is Lenoxin commonly associated with weight gain or loss?

Official safety information and clinical data do not list weight gain or loss as common side effects of Lenoxin. If you experience unexpected weight changes, it is important to discuss them with a healthcare provider.

Q: Can taking Lenoxin make me more sensitive to the sun?

Official reports on adverse reactions include general skin reactions and rashes. However, photosensitivity (increased sun sensitivity) is not explicitly listed as a common or specific adverse effect in the official regulatory documentation.

Q: Is Lenoxin considered a common or specialized medication?

The active ingredient, Digoxin, is listed on the World Health Organization's (WHO) List of Essential Medicines. This classification indicates that it is a foundational and critical medication intended for specialized cardiac support.

Q: Does Lenoxin interact with common over-the-counter pain medications like ibuprofen?

Official drug interaction lists include warnings about certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. These warnings exist because some NSAIDs can affect kidney function, which is critical for eliminating Lenoxin. The official guidance emphasizes consulting a healthcare provider before combining this medication with any over-the-counter pain relievers.

Q: How long does Lenoxin stay in your system after the last dose?

The elimination half-life is the time it takes for the concentration of the drug to be reduced by half in the body. For patients with normal kidney function, this is typically 36 to 48 hours.

Q: What is the typical duration of treatment with Lenoxin?

Lenoxin is often prescribed for long-term maintenance therapy to manage chronic heart conditions. The specific duration of treatment is determined by a healthcare provider based on the individual patient's condition and response.

Q: Can Lenoxin cause changes in sleep patterns?

Official adverse reaction reports include various Central Nervous System (CNS) effects, such as general mental disturbances and confusion. However, specific changes to sleep patterns, such as insomnia or excessive drowsiness, are not explicitly listed as common side effects in the official documentation.

Q: Does taking Lenoxin affect fertility in men or women?

Official regulatory documents contain information regarding the use of Lenoxin during pregnancy and breastfeeding. However, there is no official regulatory statement that addresses the drug's effect on general fertility in men or women.

Q: What's the difference between brand-name Lenoxin and its generic equivalent?

The active ingredient, Digoxin, is the same in both the brand-name product and its generic equivalent. Regulatory bodies certify that generic products are bioequivalent and meet the same strict standards for quality, strength, and how they function in the body.

Q: Will Lenoxin interfere with my cholesterol medication?

Official labeling advises informing a healthcare provider of all cholesterol medications, as some, such as cholestyramine, may reduce the oral absorption of Lenoxin. This ensures proper management of both therapies.

Q: Does Lenoxin cause changes in mood or anxiety levels?

Official documentation reports that Central Nervous System (CNS) effects can include mental disturbances such as anxiety, depression, delirium, and hallucinations. These potential adverse reactions, if experienced, should be reported to a healthcare professional.

Q: Can children or teenagers take Lenoxin?

Yes, Lenoxin is officially approved for use in both adults and pediatric patients, which includes children and teenagers. The dosing is carefully calculated based on the individual's age, body weight, and specific medical condition.

Q: What are the long-term effects of Lenoxin use?

Clinical trials in heart failure have monitored long-term outcomes, including rates of hospitalization and survival, over several years. Additionally, official safety warnings highlight that drug toxicity is a well-recognized risk that can occur in patients receiving long-term maintenance therapy and requires careful monitoring.

Q: Is Lenoxin only used for chronic conditions, or can it be for acute issues too?

Lenoxin is used for both. It is primarily prescribed as a tablet for long-term maintenance (chronic management) and is also available as an intravenous solution for rapid treatment initiation (acute management), known as digitalization.

Q: Do you need a special prescription for Lenoxin?

Lenoxin is classified as a prescription-only medication, meaning you must have authorization from a licensed healthcare professional to obtain it. There are no general regulatory requirements suggesting it is classified as a controlled substance or requires a special restricted prescription.

How should Lenoxin be stored and disposed of?

Storage and Disposal of Lenoxin (Digoxin)

Lenoxin (digoxin) must be stored according to regulatory requirements to ensure its stability and potency.

Storage Conditions

Requirement Details (Official Labeling)
Temperature Store below 25 C (77 F), at controlled room temperature.
Protection Keep the medication in the original container, tightly closed, and protected from excess heat, moisture, and light.
Child Safety Mandatory to keep the product out of the reach and sight of children, utilizing safety caps.
Stability The labeled shelf-life (e.g., up to 60 months for tablets) is conditional on storage within the mandated temperature range.

Disposal

Official regulatory guidelines require that unused or expired Lenoxin must be disposed of in accordance with local requirements. Patients are instructed to return expired or damaged product to a pharmacist or follow community-specific drug take-back instructions for safe disposal, avoiding flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lenoxin found in:

A-Z Index: